Skip to content

Effect of Aminophylline in treatment of severe asthma attack

Comparison of the effectiveness of nebulized aminophylline with placebo as an adjuvant in treatment of severe asthma attack

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20141115019962N3
Enrollment
70
Registered
2024-10-11
Start date
2024-09-22
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute exacerbation of asthma. Unspecified asthma with (acute) exacerbation

Interventions

Intervention 1: Intervention group: 250 mg aminophylline ( from 25 mg/ml solution) is nebulized for the patient via a face mask by a compressor nebulizer within 15 minutes. Intervention 2: Control gro

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patient older than 18 years old presented by severe asthma attack

Exclusion criteria

Exclusion criteria: Not consent for participating in the study Uncooperative for nebulizer use Contra-indications for aminophylline Pregnancy History of tachy-dysrhythmia Drug history of resent theophylline use

Design outcomes

Primary

MeasureTime frame
Admission rate. Timepoint: After 12 hours of treatment initiation. Method of measurement: Admission to inpatient wards or discharge from emergency department.;Changes in peak expiratory flow rate. Timepoint: After one hour of treatment. Method of measurement: peak-flow meter.

Secondary

MeasureTime frame
Need to intubation. Timepoint: One hour after intervention. Method of measurement: Intubated or not intubated (observation).;Severity of dyspnea. Timepoint: One hour after intervention. Method of measurement: Visual Analogue Scale.;Occurrence of adverse events of aminophylline (tachycardia, seizure, dysrhythmia and hypertension). Timepoint: One hour after intervention. Method of measurement: observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Pishbin

Mashhad University of Medical Sciences

pishbine@mums.ac.ir+98 51 3852 5312

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026